Novartis Seeks EU Fast Track For Iptacopan In Two Indications

 
• By Neena Brizmohun

Novartis will soon learn whether the European Medicines Agency will agree to grant its drug accelerated assessment status.

Calendar
An accelerated assessment can cut months off the standard review time • Source: Shutterstock

More from Review Pathways

More from Pathways & Standards